Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE trial of patiromer to enable RAAS-blocker up-titration in chronic kidney disease
NL-OMON60507Phase 4Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of patiromer and irbesartan in chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: 24-hour urinary albumin excretion adjusted for creatinine. Started May 2024; status: recruiting.
02
Drugs
patiromerirbesartan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON60507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60507.